Protease Inhibitor Compounds Balancing Potency and Selectivity

The patent applies local quality by designing inhibitors with specific molecular features at particular positions to achieve selective binding to target proteases. The compounds contain specific functional groups and structural elements (such as heterocyclic rings, peptide-like moieties, and hydrophobic regions) that interact with specific residues in the protease active site, enabling discrimination between similar protease families while maintaining high affinity for the target enzyme.

The patent employs parameter changes by systematically varying molecular parameters of the inhibitor compounds, including molecular weight, hydrophobicity, charge distribution, and structural flexibility. By optimizing these parameters within specific ranges, the invention achieves the balance between potency (requiring high affinity) and selectivity (requiring specific recognition patterns) for the target serine and cysteine proteases.

The patent reduces systemic toxicity by designing inhibitors with local quality features that enable selective accumulation at disease sites. The compounds incorporate structural elements that favor binding to overexpressed proteases in cancer cells or infected cells, while sparing normal tissues with lower protease expression. This selective targeting minimizes off-target effects and systemic toxicity.

The patent converts the potential harm of protease inhibition into a beneficial therapeutic effect by exploiting the overexpression of specific proteases in diseased states. The inhibitors target proteases that are abnormally elevated in cancer cells or virus-infected cells, transforming what could be a non-specific toxic effect into a selective therapeutic action against the diseased tissue while preserving normal physiological functions.

The patent applies universality by designing a series of related compounds with a common core structure that can inhibit multiple protease targets within the same family (serine or cysteine proteases). The inhibitors share a peptidomimetic scaffold that recognizes conserved features across family members, enabling broad-spectrum activity against related enzymes while maintaining sufficient selectivity within the therapeutic window.

The patent resolves the selectivity-versatility conflict by incorporating local quality variations in the inhibitor structures. Each compound in the series contains specific substituents or functional groups at defined positions that fine-tune the binding affinity and selectivity for particular protease targets. This allows the same core scaffold to target multiple enzymes while maintaining discriminative capability through localized structural modifications.